Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Mesothelioma
Country:  U.S.A.
Trial Type:  Treatment
Trial Phase:  Phase I
Results 1-20 of 20 for your search:
Start Over
A Study of BMS-986148 in Patients With Select Advanced Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CA008-002, NCI-2015-01329, 2014-002485-70, NCT02341625
Genetically Modified T Cells in Treating Patients with Stage III-IV Non-small Cell Lung Cancer or Mesothelioma
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2727.00, NCI-2015-00329, 2727, NCT02408016
Plicamycin in Treating Patients with Primary Thoracic Malignancies or Carcinomas, Sarcomas, or Germ Cell Tumors with Pleuropulmonary Metastases
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-C-0152, NCI-2016-01247, P152145, NCT02859415
Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: Sym013-01, NCI-2016-01802, NCT02906670
Pembrolizumab with or without Anetumab Ravtansine in Treating Patients with Mesothelin-Positive Pleural Mesothelioma
Status: Not yet active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 10107, NCI-2017-00633, MC1721, NCT03126630
Intrapleural Measles Virus Therapy in Treating Patients with Malignant Pleural Mesothelioma
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1023, NCI-2011-03574, 2010UC103, Mod1000260438, NCT01503177
A Study of LY3023414 in Participants With Advanced Cancer
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13517, NCI-2016-01472, I6A-MC-CBBA, NCT01655225
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: EMR 100070-001, NCI-2013-02214, 2013-002834-19, NCT01772004
Heated Cisplatin following Surgery in Treating Younger Patients with Primary or Metastatic Pleural Malignancies
Status: Active
Phase: Phase I
Type: Treatment
Age: 3 to 21
Trial IDs: 2012-0657, NCI-2014-01101, NCI-2014-00510, NCT01998529
Study of the Glutaminase Inhibitor CB-839 in Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CX-839-001, NCI-2014-01059, NCT02071862
Genetically Modified T Cells with or without Cyclophosphamide in Treating Patients with Recurrent Mesothelin-Expressing Cancers That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: UPCC 31213, NCI-2015-00392, 819826, NCT02159716
Mesothelin-Specific Genetically Engineered Lymphocytes with or without Cyclophosphamide in Treating Patients with Malignant Pleural Disease
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-007, NCI-2015-00789, NCT02414269
Interferon Gamma-1b and Nivolumab in Treating Patients with Metastatic Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GU-084, NCI-2016-00138, NCT02614456
Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 17631, NCI-2016-00280, NCT02639091
Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: PM1183-A-014-15, NCI-2016-01032, NCT02611024
LMB-100 with or without Nab-Paclitaxel in Treating Patients with Malignant Mesothelioma That Cannot Be Removed by Surgery
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 16-C-0127, NCI-2016-01033, P152590, NCT02798536
Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 18329, NCI-2016-01343, NCT02824042
GL-ONC1 with or without Eculizumab in Treating Patients with Solid Organ Cancers before Surgery
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: GL-ONC1-011, NCI-2016-01782, NCT02714374
Pembrolizumab after Radiation Therapy in Treating Patients with Pleural Malignant Mesothelioma
Status: Active
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 2015-0856, NCI-2016-01923, NCT02959463
Start Over